Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: Pathogenesis and therapeutic options

BACKGROUND: It has been proposed that resistance to rapalog therapies in renal cell carcinoma (RCC) is due to adaptive switching from mammalian target of rapamycin complex 1 (mTORC1) to mTORC2. OBJECTIVE: To combine phosphoprotein staining and applied biomedical analytics to investigate resistance s...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Robert E., Buryanek, Jamie, Tammisetti, Varaha S., McGuire, Mary F., Csencsits-Smith, Keri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173082/
https://www.ncbi.nlm.nih.gov/pubmed/27223432
http://dx.doi.org/10.18632/oncotarget.9508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173082/
https://www.ncbi.nlm.nih.gov/pubmed/27223432
http://dx.doi.org/10.18632/oncotarget.9508

Ejemplares similares